Journal Article

Drug-induced torsade de pointes: the perspectives of industry

L. Carlsson

in European Heart Journal Supplements

Published on behalf of European Society of Cardiology

Volume 3, issue suppl_K, pages K114-K120
Published in print September 2001 | ISSN: 1520-765X
Published online September 2001 | e-ISSN: 1554-2815 | DOI: http://dx.doi.org/10.1016/S1520-765X(01)90016-1
Drug-induced torsade de pointes: the perspectives of industry

Show Summary Details

Preview

The appearance of QT prolongation and torsades de pointes during drug treatment is often unpredictable and has been recognised as a potential risk during treatment with antiarrhythmic as well as non-antiarrhythmic drugs. As a consequence, both regulatory bodies and the pharmaceutical industry are presently addressing the importance of early preclinical testing of novel compounds to identify QT prolongation and reassure safe clinical usage of new chemical entities. This paper briefly discusses some of the suggested in vitro methodologies and the predictive value of preclinical in vivo studies for assessment of repolarization delay of novel chemical entities.

Keywords: Drugs; action potential; repolarization; QT interval; torsade de pointes

Journal Article.  0 words. 

Subjects: Cardiovascular Medicine

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.